Healthcare
By
Inside Medicare’s First Price Cuts: What a 38–79% Discount on 10 Blockbuster Drugs Means for Biopharma’s Next Decade
A data-driven look at the first round of Medicare drug price negotiation, how it compares to the pricing…
Lilly’s U.S. Pricing Play: How Volume Economics Are Rewriting the Growth Story for Zepbound and Mounjaro
Analysis of Eli Lilly’s direct-to-consumer pricing strategy and its implications for the incretin market, patient access, and competitive…
With the Only FDA-Cleared Blood Test for Alzheimer’s Risk, Can Roche’s ADLM 2026 Portfolio Bring Earlier Answers to Patients 55 and Older?
Key Highlights A Landmark Showcase Addressing Healthcare’s Systemic Workforce Challenges Roche’s presence at ADLM 2026 reflects a clear…
Can a $10 Billion Pipeline Opportunity Help Novartis Outrun Its Entresto Patent Cliff After a $5.94 Billion Profit Beat?
Key Highlights A Landmark Quarter Reinforcing Confidence in Novartis’ Growth Trajectory Novartis’ second-quarter results send an encouraging signal…
Prosper Medical’s $16M Raise Is a Bet That AI Can Make Concierge Medicine Affordable — Not Just Convenient
Analysis of Prosper Medical’s seed round, its AI-powered care model, and what it signals about the next phase…
The FDA Just Created a Reimbursement Pathway for AI-Driven Care — Here’s Why That Matters More Than the Device, Dexcom the first participant in its TEMPO pilot.
Analysis of the FDA’s TEMPO pilot, its first AI-enabled participant, and what it signals for how algorithmic health…
